Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Aul

Showing results (141-150 of 177) with videos related to

Pageof 18
Sort By:
Annals of Hematology|February 1, 1997
Acquired factor VIII inhibitors in nonhemophilic patientsD Söhngen, C Specker, D Bach, et al.
Leukemia & Lymphoma|June 27, 1998
Dyshematopoiesis in de novo acute myeloid leukemia: cell biological features and prognostic significanceG Meckenstock, C Aul, B Hildebrandt, et al.
Leukemia|July 17, 1998
Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparisonW Kern, C Aul, G Maschmeyer, et al.
Onkologie|February 1, 1989
Age related randomized comparison of sequentially applied high-dose versus intermediate dose cytosine arabinoside in combination with mitoxantrone (S-HAM) in the treatment of relapsed and refractory acute myeloid leukemia: study design and preliminary resultsW Hiddemann, C Aul, G Maschmeyer, et al.
Annals of Hematology|October 31, 1998
Granulocyte colony-stimulating factor shortens duration of critical neutropenia and prolongs disease-free survival after sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy for refractory and relapsed acute myeloid leukemia. German AML Cooperative GroupW Kern, C Aul, G Maschmeyer, et al.
Haematology and Blood Transfusion|January 1, 1990
Proposal for the classification of relapsed and refractory acute myeloid leukemias as the basis for an age-adjusted randomized comparison of sequentially applied high-dose versus intermediate-dose cytosine arabinoside in combination with mitoxantrone (S-HAM)W Hiddemann, H C Aul, G Maschmeyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1985
Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative GroupT Büchner, D Urbanitz, W Hiddemann, et al.
Klinische Wochenschrift|November 2, 1987
Acute myelofibrosis in megakaryoblastic leukemia with translocation between chromosomes 8 and 14M Winkelmann, C Aul, R E Scharf, et al.
Leukemia|October 31, 2003
Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31A A N Giagounidis, U Germing, S Haase, et al.
Leukemia|October 1, 2011
Long-term transfusion independence in del(5q) MDS patients who discontinue lenalidomideA A N Giagounidis, A Kulasekararaj, U Germing, et al.
Pageof 18

Showing results (141-150 of 177) with videos related to

Sort By:
Pageof 18
Annals of Hematology|February 1, 1997
Acquired factor VIII inhibitors in nonhemophilic patientsD Söhngen, C Specker, D Bach, et al.
Leukemia & Lymphoma|June 27, 1998
Dyshematopoiesis in de novo acute myeloid leukemia: cell biological features and prognostic significanceG Meckenstock, C Aul, B Hildebrandt, et al.
Leukemia|July 17, 1998
Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparisonW Kern, C Aul, G Maschmeyer, et al.
Onkologie|February 1, 1989
Age related randomized comparison of sequentially applied high-dose versus intermediate dose cytosine arabinoside in combination with mitoxantrone (S-HAM) in the treatment of relapsed and refractory acute myeloid leukemia: study design and preliminary resultsW Hiddemann, C Aul, G Maschmeyer, et al.
Annals of Hematology|October 31, 1998
Granulocyte colony-stimulating factor shortens duration of critical neutropenia and prolongs disease-free survival after sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy for refractory and relapsed acute myeloid leukemia. German AML Cooperative GroupW Kern, C Aul, G Maschmeyer, et al.
Haematology and Blood Transfusion|January 1, 1990
Proposal for the classification of relapsed and refractory acute myeloid leukemias as the basis for an age-adjusted randomized comparison of sequentially applied high-dose versus intermediate-dose cytosine arabinoside in combination with mitoxantrone (S-HAM)W Hiddemann, H C Aul, G Maschmeyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1985
Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative GroupT Büchner, D Urbanitz, W Hiddemann, et al.
Klinische Wochenschrift|November 2, 1987
Acute myelofibrosis in megakaryoblastic leukemia with translocation between chromosomes 8 and 14M Winkelmann, C Aul, R E Scharf, et al.
Leukemia|October 31, 2003
Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31A A N Giagounidis, U Germing, S Haase, et al.
Leukemia|October 1, 2011
Long-term transfusion independence in del(5q) MDS patients who discontinue lenalidomideA A N Giagounidis, A Kulasekararaj, U Germing, et al.
Pageof 18